D. Janson

426 total citations
9 papers, 336 citations indexed

About

D. Janson is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, D. Janson has authored 9 papers receiving a total of 336 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 5 papers in Pathology and Forensic Medicine and 3 papers in Oncology. Recurrent topics in D. Janson's work include Chronic Lymphocytic Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (5 papers) and Viral-associated cancers and disorders (2 papers). D. Janson is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (5 papers) and Viral-associated cancers and disorders (2 papers). D. Janson collaborates with scholars based in United States. D. Janson's co-authors include Mark A. Hoffman, Esther Rose, Nancy Driscoll, Shimaa A. Ahmed, Nitin Gupta, KR Rai, Darsh Patel, R. Kanti, Daniel Hogan and David Hakimian and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Leukemia.

In The Last Decade

D. Janson

8 papers receiving 323 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D. Janson United States	7	260	180	131	94	75	9	336
JF Seymour Australia	6	219 0.8×	148 0.8×	153 1.2×	124 1.3×	77 1.0×	7	341
P Travade France	7	361 1.4×	246 1.4×	230 1.8×	60 0.6×	78 1.0×	20	439
Massimo Pini Italy	10	119 0.5×	128 0.7×	115 0.9×	136 1.4×	112 1.5×	26	382
Véronique Salaün France	12	163 0.6×	185 1.0×	202 1.5×	153 1.6×	117 1.6×	27	494
Lo Ann C. Peterson United States	7	184 0.7×	148 0.8×	175 1.3×	65 0.7×	66 0.9×	10	315
S Cardona Italy	5	217 0.8×	130 0.7×	261 2.0×	57 0.6×	84 1.1×	5	379
Raúl Gabus Uruguay	10	133 0.5×	83 0.5×	149 1.1×	57 0.6×	73 1.0×	24	366
S Kotlarek-Haus Poland	6	303 1.2×	236 1.3×	152 1.2×	57 0.6×	61 0.8×	23	355
Aurélie Verney France	11	226 0.9×	224 1.2×	77 0.6×	85 0.9×	25 0.3×	16	334
Tomáš Reigl Czechia	7	105 0.4×	134 0.7×	70 0.5×	77 0.8×	43 0.6×	10	233

Countries citing papers authored by D. Janson

Since Specialization

Citations

This map shows the geographic impact of D. Janson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Janson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Janson more than expected).

Fields of papers citing papers by D. Janson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Janson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Janson. The network helps show where D. Janson may publish in the future.

Co-authorship network of co-authors of D. Janson

This figure shows the co-authorship network connecting the top 25 collaborators of D. Janson. A scholar is included among the top collaborators of D. Janson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Janson. D. Janson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Kaufman, Matthew, D. Janson, Nancy Driscoll, et al.. (2010). Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia. Medical Oncology. 28(2). 532–538. 7 indexed citations

2.

Chen, Shih‐Shih, Matthew Kaufman, Rajendra N. Damle, et al.. (2010). Efficacy and Safety of Hydroxychloroquine Sulphate In Chronic Lymphocytic Leukemia: Clinical Trial Experience In Untreated Patients. Blood. 116(21). 1392–1392.

3.

Mehrotra, Bhoomi, Nagashree Seetharamu, D. Janson, et al.. (2005). Low pretreatment hemoglobin and advanced age: Important adverse prognostic factors in head and neck cancer independent of treatment modality. A large single institutional study. Journal of Clinical Oncology. 23(16_suppl). 5524–5524. 1 indexed citations

4.

Kanti, R., Tarun Wasil, Nancy Driscoll, et al.. (2004). Clinical staging and prognostic markers in chronic lymphocytic leukemia. Hematology/Oncology Clinics of North America. 18(4). 795–805. 24 indexed citations

5.

Gupta, Nitin, Darsh Patel, D. Janson, et al.. (2002). Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia. 16(10). 2092–2095. 103 indexed citations

6.

Hoffman, Mark A., et al.. (1997). Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.. Journal of Clinical Oncology. 15(3). 1138–1142. 99 indexed citations

7.

Gartenhaus, Ronald B., et al.. (1996). The induction of p53 and WAF1/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine. Journal of Molecular Medicine. 74(3). 143–147. 25 indexed citations

8.

Hoffman, Mark A., Martin S. Tallman, David Hakimian, et al.. (1994). 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 12(4). 788–792. 66 indexed citations

9.

Siegal, Frederick P., Michael Shodell, Mark A. Hoffman, et al.. (1994). Impaired interferon alpha response in hairy cell leukemia is corrected by therapy with 2-chloro-2'-deoxyadenosine: implications for susceptibility to opportunistic infections.. PubMed. 8(9). 1474–9. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact